Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy? - Wikidata - awgldk - TriplyDB

Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?

Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?

http://www.wikidata.org/entity/Q34579919

about

Renal effects of dapagliflozin in patients with type 2 diabetes The clinical application of linagliptin in Asians The Role of Dipeptidyl Peptidase - 4 Inhibitors in Diabetic Kidney Disease Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.Linagliptin Limits High Glucose Induced Conversion of Latent to Active TGFß through Interaction with CIM6PR and Limits Renal Tubulointerstitial Fibronectin.The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes Cofilin1 is involved in hypertension-induced renal damage via the regulation of NF-κB in renal tubular epithelial cells.Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice.Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.New therapeutic agents in diabetic nephropathy.The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.The renal effects of SGLT2 inhibitors and a mini-review of the literature.Tubulointerstitial disease in diabetic nephropathy.Sodium-glucose cotransport.Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.Diabetic nephropathy: landmark clinical trials and tribulations.A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans.Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects.SGLT2 Inhibitors: Glucotoxicity and Tumorigenesis Downstream the Renal Proximal Tubule?The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors.New and old agents in the management of diabetic nephropathy.SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.Targeting inflammation in diabetic kidney disease: early clinical trials.Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes.SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical Relevance and Potential Risks.Distribution of glucose transporters in renal diseases.Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice

P2860

Q24564811-9DB043E4-D55D-4462-B830-04465831102B Q26781942-6DF4B1B6-C640-4B02-9737-DC8B3FD7AEEE Q26784454-8C2FDDF6-444F-475A-A5B5-CD05F33E7EE2 Q27010669-DED53F2A-03A1-4270-AB90-E020171857B7 Q28079134-FEDA95BB-01DE-4733-9D2E-176A9CB905A2 Q28552482-90F820DD-9EDC-4CCA-BA89-0F1B2CDD201A Q32186373-0DE96E52-8DA1-4DAF-9476-B2F49C15DB53 Q33696974-AE72694D-F4FB-45FC-947A-1664D38E0E10 Q34062829-0EF69A09-A18F-4C2F-AB7B-E0191D84FAEB Q34503796-01A1AD3D-0FA1-4D3A-8C78-124E753EA1CD Q35181821-D7C391AE-A3B9-4BFF-BD22-5EB43255EAAB Q35392355-E4D2F4CE-8ED3-40D5-A7EE-C4AC1B66CDFB Q35824459-1E0381DB-0A8B-4B14-B3D0-AD756107E12F Q35951020-B0673624-77C2-45EF-9FB4-67585FF8219B Q36142616-C5BCB6AB-5089-41CF-92B2-38747FF73FBF Q36851156-0368E1DE-C323-48B6-AB1E-AF63EBD82535 Q36937697-12AC09A6-C38C-49E5-A4F3-8D6C7BA71310 Q37219076-58A7A775-F966-4717-9A53-6FBFF0D45131 Q37559164-4DE987EE-BEB3-4FE5-83FC-2581AAB13B9B Q37559421-C3F310A1-5908-4284-8006-5EBAB9D3D828 Q37632127-23C9F7EF-DF2B-466C-8661-4A250397352A Q37669397-0590AD61-3793-42AE-B5EB-BE91321682DA Q37718851-44732000-B9E1-4DB3-A1BB-88389D805D3F Q38130748-A3A8B7FF-EFDE-4EE4-A6C1-E5B6CF4F6B1F Q38330456-1B030804-3B20-4BA8-AC4F-24E9ED0D22F7 Q38338539-5254135E-F1A3-46DB-92A0-F269DA0AAC83 Q38537119-A7FFA284-2E57-454F-B11B-E00080D8CC63 Q38635763-8625F4B2-E1F1-462C-9135-B0E576E5481A Q38667712-21CF7EA5-B086-4C1B-9B50-BE0729E2EDA4 Q38715153-BD577794-B2A5-450A-9835-34209F9C32A7 Q38738871-EF19BCA7-2E25-4D47-82CC-3AA9A9AFAA31 Q38775305-93073C2A-7BB8-4D9B-B710-25CC6A52697C Q38857166-C4A355E7-8605-4C10-ABEC-5F2C870BF282 Q38936746-7AF76B87-83A3-4A07-A872-57759FF06E58 Q38961637-3B0AF6EC-FFCF-4F55-A165-3BDD52A23E21 Q39000587-E7F05ED5-A874-4B0A-A832-A5DDC482A78E Q39170860-4EC281D4-02C2-4996-96E9-7C7D5502F1C8 Q39290337-7C532ADF-6F9F-4693-A683-B95F046931A3 Q41570521-0D2B0D47-683E-4CD3-B70B-723F8C9DEC28 Q42329981-053FB32B-A053-48F2-83A9-29E755F8C79E

P2860

Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?

http://www.wikidata.org/entity/Q34579919

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Effects of SGLT2 inhibition in ...... ction in diabetic nephropathy?

@ast

Effects of SGLT2 inhibition in ...... ction in diabetic nephropathy?

@en

Effects of SGLT2 inhibition in ...... ction in diabetic nephropathy?

@nl

type

label

Effects of SGLT2 inhibition in ...... ction in diabetic nephropathy?

@ast

Effects of SGLT2 inhibition in ...... ction in diabetic nephropathy?

@en

Effects of SGLT2 inhibition in ...... ction in diabetic nephropathy?

@nl

prefLabel

Effects of SGLT2 inhibition in ...... ction in diabetic nephropathy?

@ast

Effects of SGLT2 inhibition in ...... ction in diabetic nephropathy?

@en

Effects of SGLT2 inhibition in ...... ction in diabetic nephropathy?

@nl

P1433

Q34579919-B34F3C5C-144C-4F6D-A9E6-363B6E4E7A0E

P1476

Q34579919-B234E219-7F7E-462B-96A4-9BC3A1585B25

P2093

Q34579919-325AEC2B-5DF0-4EFD-87CF-C077D9847CCC

Q34579919-38FB66E9-7C99-4E46-8095-B4D4136C7574

Q34579919-77EB41F8-D5C1-4027-8492-F365FADAE441

Q34579919-E56FE72D-9DF7-404B-837C-49AF90BFD939

Q34579919-E77100F7-FEDB-4407-A539-5CDBA625C9BD

Q34579919-F63E8DFB-BCB9-4C79-897E-C420EC0A4016

P2860

Q34579919-0AE560B8-A78F-4C1D-818C-3532577AFE41

Q34579919-1519CB8B-CB5B-45A2-878B-6785A9429E1F

Q34579919-1BFEA9F4-7F9A-4732-8A3A-32D40B618FD3

Q34579919-1C702BB3-12A3-4B30-AF3D-D942664B7D24

Q34579919-2CCBA19F-BA3D-40C5-8069-43C9660E72D3

Q34579919-433FF791-7489-4546-9044-ECB741166A3B

Q34579919-476E2539-87D0-434E-B800-793E9C99A502

Q34579919-5C612764-C75F-4894-B51D-0696D3826DAD

Q34579919-5D0FC7D3-BB3F-4D8E-B58B-73436C1A4401

Q34579919-658B3D21-A098-4D04-B888-A88839A4D016

P304

Q34579919-6C3DAEF7-AE6B-427A-9347-9DA85216CE32

P31

Q34579919-BB0FD96C-79CB-4DC6-B48A-E82E5FFBB027

P356

Q34579919-1159D7D0-6B06-4A99-8C72-590AAC9957E8

P407

Q34579919-AFE82FED-73A9-46B7-8A11-B0EC293AE9BC

P433

Q34579919-167139C9-C3E9-4123-9CE3-B3792C199251

P478

Q34579919-26BC68C2-C40A-4A3E-B7F8-7E5129DAAC96

P50

Q34579919-089D54FF-893E-4D63-93F1-060358B40331

Q34579919-169CCEB7-DA90-4CCC-A25D-11115998AB8B

P577

Q34579919-E25067FD-AFB3-4322-9247-EE8F5E74F34C

P5875

Q34579919-2C5D51CE-ABA0-458A-87EB-EF9AB64FC9DF

P698

Q34579919-AF1ED296-1D60-4D45-A0D4-AD5042BFC87E

P932

Q34579919-C4AB1C7F-9FBD-4444-BF9D-32A961F5F25D

P356

JOURNAL.PONE.0054442

P1433

P1476

Effects of SGLT2 inhibition in ...... ction in diabetic nephropathy?

@en

P2093

Amanda Mather

http://www.w3.org/2001/XMLSchema#string

Carol Pollock

http://www.w3.org/2001/XMLSchema#string

Harshini Mudaliar

http://www.w3.org/2001/XMLSchema#string

Kate Pegg

http://www.w3.org/2001/XMLSchema#string

Simon Gross

http://www.w3.org/2001/XMLSchema#string

Usha Panchapakesan

http://www.w3.org/2001/XMLSchema#string

P2860

Biochemistry and molecular cell biology of diabetic complications

Renal Na(+)-glucose cotransporters

Tubular sodium handling and tubuloglomerular feedback in experimental diabetes mellitus

The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?

A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials.

Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.

Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease.

Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat

Role of Kruppel-like factor 6 in transforming growth factor-beta1-induced epithelial-mesenchymal transition of proximal tubule cells

P304

e54442

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0054442

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Josephine M. Forbes

Muralikrishna Gangadharan Komala

P577

2013-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235416871

http://www.w3.org/2001/XMLSchema#string

P698

23390498

http://www.w3.org/2001/XMLSchema#string

P932

3563635

http://www.w3.org/2001/XMLSchema#string